Rentschler Expands Single-Use Manufacturing Capacities
Advertisement
Rentschler Biotechnologie GmbH announced the addition of a 2,000 L single-use bioreactor to its facility in Laupheim. The expansion is anticipated to be fully operational end of the first quarter of 2015. The new 2,000 L single-use bioreactor will supplement two existing 1,000 L single-use bioreactors already in operation and will double the total single-use production capacity.
“We see an increasing need for production capacity in the mid-scale. The expansion will allow us to match the growing demands of our clients for all clinical phases. The addition of the 2,000 L single-use bioreactor will increase our flexibility to serve the market with either stainless steel or single-use technology as the client requires”, explains Frank Ternes, Chief Business Officer at Rentschler.
Most read news
Other news from the department manufacturing
These products might interest you

Flexcell Cell Stretching Bioreactors by Dunn
Cell Stretching Bioreactors for Life Science Research
Used in over 1300 laboratories worldwide, and cited in over 9000 research publications

Biostat STR by Sartorius
Biostat STR Generation 3 Bioreactors
Engineered for Ultimate Upstream Performance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Healthy cells can impact tumour progression during embryonic development - Avian embryo model of neuroblastoma

LAUDA founds subsidiary in Italy
GenOway and Boehringer Ingelheim reinforce their collaboration

Advanced dosimetry phantoms improving radiotherapy verification

Detection of cancer from exhaled breath - Breath gas analysis for medical diagnostics
Dry eye syndrome: Neuroptis successfully completes the pre-clinical phase for ML7 - Neuroptis is looking to establish industrial and financial partnerships to commence human trials
TxCell receives Fast Track Designation from FDA for Ovasave - TxCell’s lead product designated for the treatment of moderate to severe Crohn’s disease
